Extracorporeal liver support

Current Opinion in Critical Care

Volumn 19, Issue 2, 2013, Pages 149-153

  Faybik, Peter ^a   Krenn, Claus Georg ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

albumin dialysis; citrate anticoagulation; liver support

Indexed keywords

ALBUMIN; ALDOSTERONE; BENZODIAZEPINE DERIVATIVE; BILE ACID; BILIRUBIN; CITRIC ACID; COPPER; FRESH FROZEN PLASMA; MANGANESE; NITRATE; NITRIC OXIDE; NITRITE; NORADRENALIN; PHENOL DERIVATIVE; POLYSULFONE; RESIN; SHORT CHAIN FATTY ACID; THIOL; VASOPRESSIN;

ACUTE LIVER FAILURE; ANTICOAGULATION; DETOXIFICATION; HEART OUTPUT; HEART RATE; HEMODIAFILTRATION; HEMODYNAMICS; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LIVER CIRRHOSIS; LIVER METABOLISM; LIVER REGENERATION; LIVER SUPPORT; LIVER TRANSPLANTATION; LONG TERM CARE; MEAN ARTERIAL PRESSURE; OUTCOME ASSESSMENT; PLASMA RENIN ACTIVITY; REVIEW; SHORT COURSE THERAPY; SURVIVAL RATE; SYSTEMIC VASCULAR RESISTANCE;

ALBUMINS; ANTICOAGULANTS; CITRIC ACID; DIALYSIS; END STAGE LIVER DISEASE; EXTRACORPOREAL CIRCULATION; FEMALE; HUMANS; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MALE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SORPTION DETOXIFICATION;

EID: 84874769649     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32835eb970     Document Type: Review

References (35)

1. Lee WM. Acute liver failure. Semin Respir Crit Care Med 2012; 33: 36-45.
2. Bernal W, Auzinger G, Sizer E. Intensive care management of acute liver failure. Semin Liver Dis 2008; 28:188-200. (Pubitemid 351632958)
3. Rahimi RS, Rockey DC. Complications of cirrhosis. Curr Opin Gastroenterol 2012; 28:223-229.
4. Krisper P, Stadlbauer V, Stauber RE. Clearing of toxic substances: are there differences between the available liver support devices? Liver Int 2011; 31 (Suppl 3):5-8.
5. Laleman W, Wilmer A, Evenepoel P. Effect of the molecular adsorbent system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006; 10:R108.
6. Podoll AS, De Golovine A, Finkel KW. Liver support systems-a review. ASAIO J 2012; 58:443-449.
7. Boonsrirat U, Tiranathanagul K, Srisawat N. Effective bilirubin reduction by single-pass albumin dialysis in liver failure. Artif Organs 2009; 33:648-653.
8. Wauters J, Wilmer A. Albumin dialysis: current practice and future options. Liver Int 2011; 31:9-12.
9. Mitzner SR, Stange J, Klammt S. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective randomized controlled clinical trial. Liver Transpl 2000; 6:277-286. (Pubitemid 30317221)
10. Heemann U, Treichel U, Loock J. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36:949-958.
11. Banares R, Nevens F, Larsen F. Extracorporeal liver support with the molecular adsorbent recirculating system (MARS) in patients with acute-onchronic liver failure (AOCLF). The RELIEF trial. J Hepatol 2010; 52:S459-S1459.
12. Hassanein TI, Tofteng F, Brown RS. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46:1853-1862.
13. Saliba F, Camus C, Durand F. Randomized controlled multicentre trial evaluating the efficacy and safety of albumin dialysis with MARS in patients with fulminant und subfulminant hepatic failure. Hepatology 2008; 48:377A.
14. Schmidt LE, Wang LP, Hansen BA. Systemic hemodynamic effect of treatment with the molecular adsorbent recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl 2003; 9:290-297. (Pubitemid 36322332)
15. Sen S, Davies NA, Mookerjee RP. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004; 10:1109-1119. (Pubitemid 39248408)
16. Wong F, Raina N, Richardson R. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis who have failed vasoconstrictor treatment. Gut 2010; 59:381-386.
17. Rifai K. Fractioned plasma separation and adsorption: current practice and future options. Liver Int 2011; 31:13-15.
18. Kribben A, Gerken G, Haag S. Effects of fractioned plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012; 142:782-789.
19. Jalan R, Schnurr K, Moorkerjee RP. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009; 50:555-564.
20. Sort P, Navasa M, Arroyo V. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341:403-409. (Pubitemid 29362513)
21. Ortega R, Gines P, Uriz J. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36:941-948.
22. Larsen F, Schmidt L, Wendon J. Liver assisting with high-volume plasma exchange in patients with acute liver failure. Hepatology 2010; 52 (Suppl): 367A-367A.
23. Roth GA, Faybik P, Hetz H. MCP-1 and MIP3-alpha serum levels in acute liver failure and molecular adsorbent recirculating system (MARS) treatment: a pilot study. Scand J Gastroenterol 2009; 44:745-751.
24. Roth GA, Faybik P, Hetz H. Pro-inflammatory interleukin-18 and caspase-1 serum levels in liver failure are unaffected by MARS treatment. Dig Liv Dis 2009; 41:417-423.
25. Davies N, Proven A, Leckie P. The development and testing of the UCL Liver Support Device (UCL-ARSeNEL): improvement of survival in paracetamol-induced acute liver failure pigs. Hepatology 2010; 52:1092A.
26. Rozga J, Umehara Y, Trofimenko A. A novel plasma filtration therapy for hepatic failure: preclinical studies. Ther Apher Dial 2006; 10:138-144.
27. Peng Z, Wang H, CarterMJ. Acute removal of common sepsis mediators does not explain the effects of the extracorporeal blood purification in experimental sepsis. Kidney Int 2012; 81:363-369.
28. Cruz DN, Antonelli M, Fumagalli R. Early use of polymyxin B hemoperfusion in abdominal septic shock. The EUPHAS randomized controlled trial. J Am Med Assoc 2009; 301:2445-2452.
29. Bello G, Di Muzio F, Maviglia R. New membranes for extracorporeal blood purification in septic conditions. Minerva Anesthesiologica 2012; 11:1265-1281.
30. Faybik P, Hetz H, Mitterer G. Regional citrate anticoagulation in patients with liver failure supported by a molecular adsorbent recirculating system. Crit Care Med 2011; 39:273-279.
31. Faybik P, Bacher A, Kozek-Langenecker SA. Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study. Crit Care 2006; 10:R24.
32. Meijers B, Laleman W, Vermeersch P. A prospective randomized open-label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis by the Molecular adsorbent recirculating system. Crit Care 2012; 16:R20.
33. Carpentier B, Gautier A, Legallais C. Artificial and bioartificial liver devices: present and future. Gut 2009; 58:1690-1702.
34. Demetriou AA, Brown RS, Busutil RW. Prospective randomized multicentre controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004; 239:660-670. (Pubitemid 38525637)
35. Ellis AJ, Hughes RD, Wendon JA. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996; 24:1446-1451. (Pubitemid 26399048)